Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Axovant

- PMLiVE

Axovant drops last ‘legacy’ drug to focus on gene therapies

Decision comes after nelotanserin failed to meet efficacy target

- PMLiVE

Axovant licenses another gene therapy as new strategy beds in

Group pursues gene therapy strategy

- PMLiVE

Axovant poaches Allergan’s and Teva’s chief medical and science officers

Gavin Corcoran and Michael Hayden join the biopharma

- PMLiVE

After Axovant shock, Roivant pens diabetes deal with Poxel

Acquires Merck Serono’s diabetes candidate imeglimin as part of the deal

- PMLiVE

Axovant joins ever-growing Alzheimer’s failure club

5-HT6 inhibitor Intepirdine followsin the footsteps of Lundbeck's idalopirdine

- PMLiVE

Lundbeck trial failure dashes hopes in Alzheimer’s once again

Phase III trial fails to substantially improve cognition despite promising phase II data

- PMLiVE

Axovant takes Alzheimer’s drug into phase III

Aims to bring first treatment in a decade to market

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links